Table 2. All-grade treatment-related AEs: SAS cluster.
| AEs | TACE + anlotinib (N=18) | |
|---|---|---|
| Grade 1–2 | ≥ Grade 3 | |
| All adverse reactions | 13 (72.2) | 2 (11.1) |
| HFSR | 11 (61.1) | 0 |
| Hypertension | 5 (27.7) | 0 |
| Thrombocytopenia | 1 (5.6) | 1 (5.6) |
| QT prolongation syndrome | 0 | 1 (5.6) |
| Blurred vision | 1 (5.6) | 0 |
| Hypothyroidism | 1 (5.6) | 0 |
| Proteinuria | 1 (5.6) | 0 |
| Oral mucositis | 1 (5.6) | 0 |
| Rash | 1 (5.6) | 0 |
| Leukopenia | 1 (5.6) | 0 |
| Hypoproteinemia | 1 (5.6) | 0 |
| Fatigue | 1 (5.6) | 0 |
| Anemia | 1 (5.6) | 0 |
| Vomiting | 1 (5.6) | 0 |
| Toothache | 1 (5.6) | 0 |
| Cough | 1 (5.6) | 0 |
| Epistaxis | 1 (5.6) | 0 |
Data are presented as n (%). QT, QT interval, which is a measure of the time it takes for the heart’s electrical system to reset after each heartbeat. Prolongation of the QT interval can indicate an increased risk of heart arrhythmias. AEs, adverse events; SAS, safety analysis set; HFSR, hand-foot skin reaction; TACE, transarterial chemoembolization.